Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients

Briete Goorts; Thiemo J. A. van Nijnatten; Linda de Munck; Martine Moossdorff; Esther M. Heuts; Maaike de Boer; Marc B. I. Lobbes; Marjolein L. Smidt

doi:10.1007/s10549-017-4155-2

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients

Briete Goorts^*, Thiemo J. A. van Nijnatten, Linda de Munck, Martine Moossdorff, Esther M. Heuts, Maaike de Boer, Marc B. I. Lobbes, Marjolein L. Smidt

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	83-91
Number of pages	9
Journal	Breast Cancer Research and Treatment
Volume	163
Issue number	1
DOIs	https://doi.org/10.1007/s10549-017-4155-2
Publication status	Published - May 2017

Keywords

Breast cancer
Pathological complete response
Neoadjuvant chemotherapy
Tumor size
Survival
RECTAL-CANCER
DOXORUBICIN
SURVIVAL
THERAPY
WATCH
WAIT

Cite this

Goorts, B., van Nijnatten, T. J. A., de Munck, L., Moossdorff, M., Heuts, E. M., de Boer, M., Lobbes, M. B. I., & Smidt, M. L. (2017). Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 163(1), 83-91. https://doi.org/10.1007/s10549-017-4155-2

Goorts, Briete ; van Nijnatten, Thiemo J. A. ; de Munck, Linda ; Moossdorff, Martine ; Heuts, Esther M. ; de Boer, Maaike ; Lobbes, Marc B. I. ; Smidt, Marjolein L. / Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. In: Breast Cancer Research and Treatment. 2017 ; Vol. 163, No. 1. pp. 83-91.

@article{dc220dcb2056436288ef8510676207bc,

title = "Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients",

keywords = "Breast cancer, Pathological complete response, Neoadjuvant chemotherapy, Tumor size, Survival, RECTAL-CANCER, DOXORUBICIN, SURVIVAL, THERAPY, WATCH, WAIT",

author = "Briete Goorts and {van Nijnatten}, {Thiemo J. A.} and {de Munck}, Linda and Martine Moossdorff and Heuts, {Esther M.} and {de Boer}, Maaike and Lobbes, {Marc B. I.} and Smidt, {Marjolein L.}",

year = "2017",

month = may,

doi = "10.1007/s10549-017-4155-2",

language = "English",

volume = "163",

pages = "83--91",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer, Cham",

number = "1",

}

Goorts, B, van Nijnatten, TJA, de Munck, L, Moossdorff, M, Heuts, EM , de Boer, M , Lobbes, MBI & Smidt, ML 2017, 'Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients', Breast Cancer Research and Treatment, vol. 163, no. 1, pp. 83-91. https://doi.org/10.1007/s10549-017-4155-2

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. / Goorts, Briete; van Nijnatten, Thiemo J. A.; de Munck, Linda; Moossdorff, Martine; Heuts, Esther M.; de Boer, Maaike ; Lobbes, Marc B. I.; Smidt, Marjolein L.

In: Breast Cancer Research and Treatment, Vol. 163, No. 1, 05.2017, p. 83-91.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients

AU - Goorts, Briete

AU - van Nijnatten, Thiemo J. A.

AU - de Munck, Linda

AU - Moossdorff, Martine

AU - Heuts, Esther M.

AU - de Boer, Maaike

AU - Lobbes, Marc B. I.

AU - Smidt, Marjolein L.

PY - 2017/5

Y1 - 2017/5

KW - Breast cancer

KW - Pathological complete response

KW - Neoadjuvant chemotherapy

KW - Tumor size

KW - Survival

KW - RECTAL-CANCER

KW - DOXORUBICIN

KW - SURVIVAL

KW - THERAPY

KW - WATCH

KW - WAIT

U2 - 10.1007/s10549-017-4155-2

DO - 10.1007/s10549-017-4155-2

M3 - Article

VL - 163

SP - 83

EP - 91

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -

Access to Document

10.1007/s10549-017-4155-2